Abbott Boosts Investment in NRF2 Activators for Reducing Oxidative Stress

Abbott has agreed to $400 million in upfront payments to Reata Pharmaceuticals to develop a series of second-generation oral antioxidant inflammation modulators that potently activate NFE2-related factor 2 (NRF2), a putative drug target for ALS and other diseases marked by free radical damage and inflammation.

Click here to read more.

Share this: